Nivolumab in Treating Patients With HTLV-Associated T-Cell Leukemia/Lymphoma
Summary
The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →
Investigators
The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.
- Lee Ratner
Duke University - Duke Cancer Institute LAO
Principal Investigator
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
6 registered facilities, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Johns Hopkins University/sidney Kimmel Cancer Center
Baltimore, Maryland, United States
- Nci - Center for Cancer Research
Bethesda, Maryland, United States
- National Institutes of Health Clinical Center
Bethesda, Maryland, United States
- Montefiore Medical Center - Moses Campus
The Bronx, New York, United States
- Montefiore Medical Center-Einstein Campus
The Bronx, New York, United States
- Ohio State University Comprehensive Cancer Center
Columbus, Ohio, United States
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →
Registration & key dates
Registry attributes as recorded on the ClinicalTrials.gov study record.
- Start
- 23 Feb 2017
- Primary completion
- 30 Mar 2018
- Completion
- 31 Jul 2019
- Last update posted
- 14 Mar 2025
- Registered enrollment
- 3
- Registry id
- NCT02631746
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.